Patents by Inventor Mitsunori Kato

Mitsunori Kato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
    Patent number: 10301278
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: May 28, 2019
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Sarah Williams, Martin Sendzik
  • INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20190119254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 25, 2019
    Inventors: Christopher M. ADAMS, Doug BEVAN, Michael Paul CAPPARELLI, Takeru EHARA, Luciana FERRARA, Nan Ji, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA, Nello MAINOLFI, Mitsunori KATO
  • Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 10208018
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 19, 2019
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Doug Bevan, Michael Paul Capparelli, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Nello Mainolfi, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna
  • 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20180362496
    Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 20, 2018
    Applicant: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Jorge Garcia Fortanet, Denise Grunenfelder, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Travis Matthew Stams, Sarah Williams
  • 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
    Patent number: 10093646
    Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 9, 2018
    Assignee: Novartis AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Jorge Garcia Fortanet, Denise Grunenfelder, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Travis Matthew Stams, Sarah Williams
  • N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
    Patent number: 10077276
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: September 18, 2018
    Assignee: Novartis AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Troy Douglas Smith, Sarah Williams, John William Giraldes, Martin Sendzik, Bakary-Barry Toure
  • N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20180201623
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 19, 2018
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 9957254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: May 1, 2018
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Philippe Bolduc, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna
  • N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
    Patent number: 9938295
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: April 10, 2018
    Assignee: Novartis AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Troy Douglas Smith, Sarah Williams, John William Giraldes, Martin Sendzik, Bakary-Barry Toure
  • 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20180065949
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: October 5, 2017
    Publication date: March 8, 2018
    Inventors: Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Sarah Williams, Martin Sendzik
  • 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
    Patent number: 9815813
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: November 14, 2017
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Sarah Williams, Martin Sendzik
  • Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 9765067
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 19, 2017
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Takeru Ehara, Luciana Ferrara, Nan Ji, Donglei Liu, Erik Meredith, Muneto Mogi, James Powers, Ganesh Prasanna, Mitsunori Kato
  • 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20170204080
    Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 20, 2017
    Applicant: NOVARTIS AG
    Inventors: Christine Hiu-tung CHEN, Zhuoliang CHEN, Jorge Garcia FORTANET, Denise GRUNENFELDER, Rajesh KARKI, Mitsunori KATO, Matthew J. LAMARCHE, Lawrence Blas PEREZ, Travis Matthew STAMS, Sarah WILLIAMS
  • THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197950
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Takeru EHARA, Luciana FERRARA, Nan JI, Donglei LIU, Erik MEREDITH, Muneto MOGI, James POWERS, Ganesh PRASANNA, Mitsunori KATO
  • CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197941
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Philippe BOLDUC, Takeru EHARA, Luciana FERRARA, Nan JI, Mitsunori KATO, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA
  • INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197940
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, Doug BEVAN, Michael Paul CAPPARELLI, Takeru EHARA, Luciana FERRARA, Nan JI, Mitsunori KATO, Nello MAINOLFI, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA
  • N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20170015680
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: January 16, 2015
    Publication date: January 19, 2017
    Applicant: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Troy Douglas Smith, Sarah Williams, John William Giraldes, Martin Sendzik, Bakary-Barry Toure
  • 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20170001975
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: January 16, 2015
    Publication date: January 5, 2017
    Applicant: NOVARTIS AG
    Inventors: Zhuoliang CHEN, Michael DORE, Jorge Garcia FORTANET, Rajesh KARKI, Mitsunori KATO, Matthew J. LAMARCHE, Lawrence Blas PEREZ, Sarah WILLIAMS, Martin SENDZIK
  • Furopyridine compounds and uses thereof
    Patent number: 8324239
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: December 4, 2012
    Assignee: Novartis AG
    Inventors: David Barnes, Rajiv Chopra, Scott Louis Cohen, Jiping Fu, Mitsunori Kato, Peichao Lu, Mohindra Seepersaud, Wei Zhang
  • Furopyridine compounds and uses thereof
    Publication number: 20120015907
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: April 19, 2011
    Publication date: January 19, 2012
    Applicant: NOVARTIS AG
    Inventors: David BARNES, Rajiv CHOPRA, Scott Louis COHEN, Jiping FU, Mitsunori Kato, Peichao LU, Mohindra SEEPERSAUD, Wei ZHANG